Talniflumate (Genaera).
Talniflumate, an anti-inflammatory molecule that was originally developed by Laboratorios Bago, is currently being developed by Genaera as a mucoregulator for the treatment of cystic fibrosis, chronic obstructive pulmonary disease and asthma. Phase I trials with talniflumate had been completed by August 2001, and phase II trials were underway in Ireland for the treatment of cystic fibrosis.
Knight
Darryl
D
Experimental Biology Division, Asthma & Allergy Research Institute, Department of Medicine, Sir Charles Gairdner Hospital, University of Western Australia, Hospital Avenue, Nedlands, WA 6009, Australia. dknight@cyllene.uwa.edu.au
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy; D001572:Benzofurans / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D018118:Chloride Channels / Q000187:drug effects / Q000378:metabolism; D002986:Clinical Trials as Topic; D003550:Cystic Fibrosis / Q000188:drug therapy; D005100:Expectorants / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy; D011725:Pyridines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D012852:Sinusitis / Q000188:drug therapy; D013329:Structure-Activity Relationship
D000893:Anti-Inflammatory Agents; D001572:Benzofurans; D018118:Chloride Channels; D005100:Expectorants; D011725:Pyridines; C488233:talniflumate